Back

Hutchmed shares rise more than 3% as lung cancer therapy reaches FDA filing

Verifying
  • Hutchmed shares rose as investors focused on its lung cancer combination therapy.
  • Shares gained more than 3% at one point in Hong Kong trading on September 30.
  • Hutchmed formally submitted the treatment to the U.S. Food and Drug Administration.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Hutchmed shares rise more than 3% as lung cancer therapy reaches FDA filing - CoinPost Terminal